| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Triple therapy for atrial fibrillation and percutaneous coronary intervention: a contemporary review.
|
J Am Coll Cardiol
|
2014
|
2.05
|
|
2
|
Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome).
|
J Am Coll Cardiol
|
2013
|
1.51
|
|
3
|
Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial.
|
Am Heart J
|
2014
|
1.46
|
|
4
|
Effect of Pre-Hospital Ticagrelor During the First 24 h After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction: The ATLANTIC-H(24) Analysis.
|
JACC Cardiovasc Interv
|
2016
|
1.42
|
|
5
|
Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial.
|
J Am Coll Cardiol
|
2014
|
0.85
|
|
6
|
Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial).
|
Am J Cardiol
|
2013
|
0.81
|
|
7
|
Polymorphism of the cystatin C gene in patients with acute coronary syndromes: Results from the PLATelet inhibition and patient Outcomes study.
|
Am Heart J
|
2014
|
0.78
|
|
8
|
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
|
Am Heart J
|
2016
|
0.78
|
|
9
|
Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial, International Journal of Cardiology, 2013.
|
Int J Cardiol
|
2013
|
0.75
|
|
10
|
No misrepresentation of vital status follow-up in PLATO: predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, International Journal of Cardiology, 2013 Serebruany VL. Discrepancies in the primary PLATO trial publication and the FDA reviews, International Journal of Cardiology, 2014.
|
Int J Cardiol
|
2014
|
0.75
|
|
11
|
Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Results From the PEGASUS-TIMI 54 Trial.
|
J Am Coll Cardiol
|
2017
|
0.75
|
|
12
|
Genetics of response to antiplatelet therapy.
|
Prog Mol Biol Transl Sci
|
2014
|
0.75
|
|
13
|
Dyspnea related to reversibly-binding P2Y12 inhibitors: A review of the pathophysiology, clinical presentation and diagnostics.
|
Int J Cardiol
|
2015
|
0.75
|